Osimertinib

Osimertinib
Clinical data
Trade names	Tagrisso, others
Other names	AZD9291, mereletinib, osimertinib mesilate (JAN JP), osimertinib mesylate (USAN US)
AHFS/Drugs.com	Monograph
MedlinePlus	a616005
License data	US DailyMed: Osimertinib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	L01EB04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	Probably high
Metabolism	Oxidation (CYP3A)
Elimination half-life	48 hours
Excretion	Feces (68%), urine (14%)
Identifiers
	IUPAC name N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide;
CAS Number	1421373-65-0;
PubChem CID	71496458;
DrugBank	DB09330;
ChemSpider	31042598;
UNII	3C06JJ0Z2O;
KEGG	D10766;
ChEBI	CHEBI:90943 ;
PDB ligand	YY3 (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID501025961 ;
Chemical and physical data
Formula	C28H33N7O2
Molar mass	499.619 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C;
	InChI InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32); Key:DUYJMQONPNNFPI-UHFFFAOYSA-N;

Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

Osimertinib was approved for medical use in the United States in November 2015, and in the European Union in February 2016.